PMC7531809_01
Timeline of events regarding location, SARS-CoV-2 test results, symptoms, serology, and steroid usage. Legend:  Positive SARS-CoV-2;  Negative SARS-CoV-2
42399_2020_548_Fig1_HTML.jpg
PMC7531809_01_42399_2020_548_Fig1_HTML.jpg
Fig1
Thorough diagnostic workup raised the suspicion of a secondary demyelinating disease, and the patient was started on high-dose steroids (methylprednisolone 1 g/day for 3 days followed by prednisolone 1 mg/Kg/day) (Fig. 1).
Chest computed tomography from July 6 showing a subpleural focal ground-glass densification area in the right lateral basal segment (arrow)
42399_2020_548_Fig2_HTML.jpg
PMC7531809_01_42399_2020_548_Fig2_HTML.jpg
Fig2
While at home (July 6), he had chest computed tomography (CT), which had been ordered to exclude signs of sarcoidosis as part of the secondary demyelinating disease workup and which revealed a peripheral ground-glass opacity compatible with early COVID-19 (Fig. 2).
Chest computed tomography from July 15 showing diffuse bilateral ground-glass opacities with some areas of "crazy-paving" pattern and extensive subpleural consolidation of the lower lobes
42399_2020_548_Fig3_HTML.jpg
PMC7531809_01_42399_2020_548_Fig3_HTML.jpg
Fig3